RBC Capital lowered the firm’s price target on Regeneron (REGN) to $943 from $1,051 but keeps an Outperform rating on the shares after its Q1 results. Eylea challenges remained apparent in the quarter, and the market clearly has not moved beyond it, though the stock is looking “close to floor” on valuation, the analyst tells investors in a research note. More pipeline news is coming however, so anything encouraging for that or Eylea regulatory should be all upside, RBC adds.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $633 from $768 at UBS
- Regeneron price target lowered to $587 from $652 at Baird
- Regeneron price target lowered to $800 from $865 at BMO Capital
- Regeneron price target lowered to $700 from $750 at Wells Fargo
- Evan Seigerman’s Buy Rating on Regeneron: Overcoming Challenges with a Promising Pipeline and Undervalued Assets